Search
Mesothelioma Treatment Options Asbestos Exposure News Veterans And Mesothelioma About ELSS FREE Case Evaluation Top Mesothelioma Doctors

Shahriyour Andaz, M.D.
Dr. Shahriyour Andaz of South Nassau Communities Hospital on Long Island, NY is one of the foremost area experts in the treatment of malignant mesothelioma.

H. Ian Robins, M.D.
Dr. H. Ian Robins is chairman of the Systemic Hypothermia Oncological working group at the University of Wisconsin Hospital and Clinics specializing in malignant mesothelioma.

This website is certified by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information:
verify here.

Free Mesothelioma Information Packet

Enter your information to receive a comprehensive mesothelioma packet free of charge at your doorstep within 24 hours.

Yes   No

Evaluation of Membranous Staining of Mesothelioma.

Panels of immunohistochemical markers are often used to aid in categorizing malignant neoplasms involving the pleura. While epithelial membrane antigen (EMA) and human milk fat globule-2 (HMFG-2) are each reported to stain the majority of cases of adenocarcinoma and mesothelioma, authors have reported that the pattern of staining for these two antibodies can be a useful discriminant. Both are described as revealing a membranous pattern of staining for mesothelioma and a cytoplasmic staining pattern in adenocarcinoma. Immunostains were performed on 23 cases of malignant mesothelioma and 22 cases of adenocarcinoma. For EMA, 78% of mesotheliomas and 86% of adenocarcinomas stained positively, and 65% of mesotheliomas vs. 14% of adenocarcinomas exhibited a membranous staining pattern. For HMFG-2, 9% of mesotheliomas and 50% of adenocarcinomas stained positively, and 4% of mesotheliomas vs. 9% of adenocarcinomas exhibited a membranous staining pattern. Membranous staining for HMFG-2 was not a useful criterion. In this series, a membranous pattern of staining for EMA had a sensitivity of 65% and a specificity of 86% for the identification of malignant mesothelioma.

Source

PMID: 9660721, UI: 98320097
Click here to order or save article

If you have any questions regarding treatment options or your legal rights, please contact us.